Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D

Arrowhead Pharmaceuticals, Inc. today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference based medicines that utilize the...

Related Keywords

Christopher Anzalone , Exchange Commission , Arrowhead Pharmaceuticals , Nasdaq , Arrowhead Pharmaceuticals Inc , Linkedin , Summer Series , Series Schedule , Nervous System , Harbor Statement , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports ,